Lunai Bioworks Inc.
RENB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.00 | -1.13 | 0.06 |
| FCF Yield | -4.72% | -0.38% | 13,391,513.58% | -1.89% |
| EV / EBITDA | -9.39 | -3.85 | 231.32 | -19.85 |
| Quality | ||||
| ROIC | 32.01% | 1,135.60% | -4.34% | -5.14% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.48 | 0.01 | 0.30 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 577,735.77% | 577,735.77% | 566,037.84% | 566,037.84% |
| Free Cash Flow Growth | 25.51% | -100.00% | 461,155,576.13% | -26.95% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | -0.08 | 16.24 | -0.85 |
| Interest Coverage | 27.03 | -675.00 | -22.07 | -39.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -11,713.99 | -33,005.32 | -30,649.04 |